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Abstract 
Background: MiroCam®, a capsule endoscope, utilizes a novel transmission technology, electric-
field propagation that uses the human body as a conductive medium for data transmission. 
Objective: To compare the ability of the MiroCam® (MC) and PillCam® (PC) to identify sources of 
obscure GI bleeding (OGIB)  
Design: Prospective, multicenter, comparative study. 
Setting: Six academic hospitals. 
Patients: 105 patients with OGIB. 
Interventions: Subjects ingested both the MC and PC capsules sequentially in a randomized 
fashion.  
Main outcome measurements: Concordance of rates in identifying a source of OGIB, operational 
times and rates of complete small bowel examination. 
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Results: Data analysis resulted in 43 (48%) "abnormal" cases identifying a source of OGIB by 
either capsule. Twenty-four cases (55.8%) were positive by both capsules. There was negative 
agreement in 46/58 cases (79.3%).  The κ-index was 0.547 (χ2=1.32, p=0.36).  In 12 cases, MC 
positively identified a source that was not seen on PC; whereas in 7 cases, PC positively identified 
a source that was not seen on MC. MC had a 5.6% higher rate of detecting small bowel lesions 
(p=0.54). MC captured images at 3 frames/sec for 11.1 hours and PC captured images at 2 
frames/sec for 7.8 hours (p< 0.0001). Complete small bowel examination was achieved in 93.3% 
for MC and 84.3% for PC (p=0.10).   
Limitations: Readers could not blinded to the particular capsule they were reading. 
Conclusions: A positive diagnostic finding for OGIB was identified by either capsule in 48% of 
cases.   The concordance rate between the 2 capsules was comparable to prior studies in 
identifying sources of small bowel bleeding. The longer operational time of the MC may result in 
higher rates of complete small bowel examination which may, in turn, translate into a higher rate 
of detecting small bowel lesions. 
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INTRODUCTION 
 
Since its first report over a decade ago, capsule endoscopy (CE) has revolutionized the evaluation 
of patients with suspected small bowel disease and is now considered the test of choice in the 
evaluation of obscure gastrointestinal bleeding (OGIB) 1. Two small bowel CE systems (Pillcam 
SB2®, Given Imaging, Yoqneam, Israel, and Endocapsule®, Olympus America, Allentown, PA) are 
currently being used in the United States 2. Both systems use radiofrequency to transmit images 
from the device to an external receiver. 
  
In 2009, a Korean group reported on the safety and efficacy of a new type of capsule endoscope, 
the MiroCam® (MC), which utilizes a novel transmission technology known as electric-field 
propagation 3. With this technology, the human body serves as the medium for data 
transmission, propagating low voltage signals through a pair of gold plates on the surface of the 
capsule device. The low voltage requirement results in lower power consumption, allowing for a 
longer operation time, and a device, which captures a greater number of images compared to 
capsules that utilize radiofrequency transmission.   
 
We report the results of a multicenter study comparing PillCam SB2® (PC) and MC capsules 
swallowed sequentially in randomized order by patients with OGIB. The primary study endpoint 
was the identification of a bleeding source.  
 
METHODS 
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Patient enrollment 
Between January 2009 and July 2010, 105 patients with suspected small bowel bleeding were 
competitively enrolled into the study at six US academic sites.  
 
All patients underwent a prior esophagogastroduodenoscopy (EGD) and colonoscopy within the 
previous 12 months or clinically demonstrated continued bleeding, requiring blood transfusions 
since their initial evaluation. Enrolled patients needed to demonstrate a hemoglobin value of < 
11g/dL (or < 13g/dL if documented iron deficient anemia) in males or < 10g/dL (or < 12g/dL if 
documented iron deficient anemia) in females within 30 days of capsule endoscopy or prior to 
transfusions if transfusions were clinically necessary. Patients needed to be referred for a capsule 
endoscopy as part of their diagnostic evaluation and needed to be competent and willing to sign 
a written informed consent.  
 
Patients with a diagnosis or suspicion of a gastrointestinal obstruction, stricture, perforation, 
swallowing disorder, significant loss of gastrointestinal motility, three or more known small 
bowel diverticula, radiation or chemotherapy-induced enteritis, history of skin allergy or 
sensitivity to adhesives were excluded from the study. Pregnant patients, patients who were not 
candidates for surgical intervention, and patients with a cardiac pacemaker, defibrillator or 
another type of implanted electro-mechanical device, as well as patients who were scheduled for 
an MRI and those who had participated in another research study within the last 30 days were 
also excluded.  
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Capsule endoscope preparation and administration 
At the time of a study initiation visit, all patients underwent a complete physical examination, 
review of their medical and medication history, and a urine pregnancy test as indicated. Starting 
38 hours prior to capsule ingestion, all study participants were instructed to consume a liquid 
diet for 24 hours, consume only water for the following 12 hours, and then fast for at least 2 
hours prior to the procedure.  
 
On the day of the procedure, patients were fitted with receivers and sensors as recommended by 
both manufacturers and ingested both capsules in a randomized order 90 minutes apart. They 
were accordingly placed in an alternating fashion into a "MC-first" or "PC-first" cohort by 
competitive enrollment. Each subject was given a “subject number” to conceal the identity of the 
patient. Only the study coordinators were aware of the subject numbers, which corresponded to 
the patient identity. All subjects wore the receivers for 11 hours after ingestion of the second 
capsule. They were allowed to ingest up to 4 ounces of water to facilitate ingestion of each 
capsule. Patients were provided an anti-foaming agent (simethicone or an equivalent alternative) 
to swallow within five minutes prior to capsule ingestion. Subjects remained at the recruitment 
site for 30 minutes after swallowing the second capsule for observation and to document any 
complaints.  
 
Receivers were returned the day of the procedure or the following business day.  Patients were 
subsequently interviewed and instructed to call the office to report the date and time of capsule 
passage. Patients who were unable to verify capsule passage were followed with serial 
abdominal radiographs until passage of the device was confirmed. 
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Image interpretation 
All images were collected from each capsule and were interpreted by two independent 
experienced readers, who were blinded to the particular subject and the interpretation of the 
other reader. They were not blinded to the source of the images (MC versus PC) on account of 
the differing image-viewing software programs and respective image qualities. Readers were 
given the freedom to use their own preferred viewing mode (single /dual / quad) and viewing 
speed, but were required to use the same reading preferences for evaluating the MC and PC 
images. A pair of readers was randomly selected from a pool of five reader pairs and these two 
reviewers read both sets of images (MC and PC) for each individual subject. The reader pairs 
were presented the image sets for any given subject with all subject-identifying information 
masked at separated time points to prevent bias. The reader pairs remained fixed for the 
duration of the trial.  In situations in which the two readers reviewing the same capsule images 
for a given subject did not agree in their diagnostic findings, an adjudication committee, 
consisting of three members, who were not part of the reader pool, was asked to review the 
images for the respective capsule to determine a diagnosis, which was then considered the final 
diagnosis for the respective capsule. The adjudication committee was blinded to the findings of 
the opposing capsule for all cases.  
 
Image interpretation bias was minimized by using independent readers rather than site 
investigators to interpret the imaging files and by blinding each reader to the findings of the 
other readers. The interpretation of an abnormal finding was chosen from a predetermined list of 
possible diagnoses including: ulcerative lesions, tumor/polyp, vascular lesions (AVM), blood 
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(without ability to identify the lesion), and "other".  To be considered concordant, it was 
necessary for the responses provided by the readers to agree on the specific finding. 
 
Statistical analysis 
A sample size of 85 subjects was determined to allow for the detection of a concordance rate of 
at least 85% with a two-sided 95% confidence interval of 12% between MC and PC. A total of 105 
subjects were enrolled in the study to allow for subject dropout or for not meeting criteria for the 
effectiveness evaluation at a rate of 20-25%.  All study subjects, who ingested at least one 
capsule, were included in the safety analyses as an intention to treat analysis. A chance-adjusted 
kappa statistic was calculated to evaluate the strength of the agreement between MC and PC 
with respect to the detection and identification of sources of small bowel bleeding.  The 
concordance rate and corresponding 95% confidence interval was estimated. An 85% 
concordance rate was predetermined to be evidence of equivalence between the MC and PC. 
The mean total transit times through specific anatomic landmarks (esophagus, stomach, small 
bowel and colon), mean total transit times from ingestion to capsule expulsion, and mean total 
operation times of the MC and PC were compared using the paired t-test at the 5% significance 
level.  An exploratory analysis of variance, including the order of ingestion of the two capsules, 
was performed to assess for the potential impact of the order in which the two capsules were 
ingested. 
 
The percent of MC capsules reaching the cecum during the operation time of the MC capsule 
compared to the PC was tested using the McNemar test at the 5% significance level. The 
concordance between MC and PC with respect to detection of sources of small bowel bleeding 
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was assessed using the chance-adjusted kappa statistic, and the estimated concordance rate with 
the corresponding 95% confidence interval was evaluated. 
 
IRB approval 
The study was approved by the Institutional Review Board of each participating center prior to 
patient enrollment. Each patient signed an informed consent form prior to enrollment. 
 
RESULTS 
A total of 105 patients were prospectively recruited into the study for obscure GI bleeding among 
the six institutions. The clinical features of the study subjects are listed in Table 1. Fifty-two 
patients were randomized to ingest the MC capsule first and fifty-three patients ingested the PC 
first. Forty-two of the patients in the MC first cohort had evaluable data, and 47 of the patients in 
the PC first cohort had evaluable data (Figure 1).  As a result, 16 patients were excluded from this 
study for various reasons, including 10 cases of <2 hours of evaluable data on either capsule, one 
case of being lost to follow-up, four cases of lack of imaging data and one case of voluntary 
patient withdrawal from the study.  Of the four cases of lack of imaging data, two cases were due 
to gastric retention of the PC (the MC passed into the small bowel and obtained evaluable data), 
and one case of both the MC and PC being retained in the stomach. There was one case of 
inability to properly upload the MC data and the subsequent loss of data. This issue was rectified 
by re-training the staff on equipment use. A total of 89 patients were therefore included in the 
final analysis. 
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Capsule concordance by either “normal” or “abnormal” results 
Data analysis of the 2 capsules for a dichotomized result of "normal" or "abnormal" 
demonstrated 43 (48.3%) positive cases in which there was an identifiable source of OGIB by 
either capsule.  Paired responses of the 89 cases are shown in Table 3. Of the 89 cases, both 
devices reported normal findings in 46 cases, and abnormal findings in 24 cases. Of the remaining 
19 cases, the devices disagreed in their findings, with MiroCam reporting a normal finding to 
PillCam’s abnormal finding in 7 cases, and a MiroCam finding of abnormal to PillCam’s normal 
finding in 12 cases. These data represent an overall concordance of 78.7% (95% CI, 68.7-86.6%), a 
positive agreement of 77.4% (95% CI, 58.9-90.4%), and a negative agreement of 79.3% (95% CI, 
66.7-88.8%) (Table 4).  McNemar’s test was conducted to determine whether the disagreements 
between the two capsules occurred randomly as opposed to being biased in one direction or the 
other. The total of 19 disagreements, which split into 12 and 7 as indicated above, gives rise to a 
p-value of 0.36 (chi-square=1.32 on one degree of freedom) and indicates that there is no 
evidence of a statistically significant difference between the two capsules in detecting small 
bowel lesions. The overall k coefficient was 0.55 (95% CI 0.37-0.72).   
 
Capsule concordance by type of lesion 
The most frequent positive findings at capsule endoscopy were vascular lesions (Table 5): MC 
detected vascular lesions in 15 of 89 patients (16.9%), while PC detected 14 cases of vascular 
lesions (15.7%). The second most common finding was that of blood without an identifiable 
lesion: MC detected 10 such cases (11.2%), while the PC detected 11 cases (12.4%). 
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PC was read as "normal" in twelve patients (13.48 %) in which MC detected a lesion: 6 vascular 
lesions, 3 cases of blood without an identifiable source, 2 cases of ulcers, and 1 tumor/polyp. MC 
was read as "normal" in 7 patients (7.9%) in which PC detected a lesion: 3 vascular lesions, 3 
cases of blood without an identifiable source, and 1 tumor/polyp.  
 
Transit and operational times for MiroCam vs. PillCam 
The transit times of the respective capsules were evaluated by their transit through the 
esophagus, stomach, small bowel and to complete expulsion per rectum (Table 6). An equal 
number of capsules (n=74) could be evaluated for total gastrointestinal tract transit time, and 
there was no statistical difference by capsule type. However, a greater percentage of MC 
capsules reached the cecum (93.3%) as opposed to PC (84.3%),  although this was not statistically 
significant (p= 0.10). 
 
There were 15 subjects in which at least one capsule did not remain operational until the cecum. 
In 5 cases, both the MC and PC capsules endoscopes did not record data to the cecum. In 9 cases, 
the PC capsules were not operational until the cecum, when the paired MC remained 
operational.  There was one case in which the MC was not operational to the cecum, when the 
paired PC remained operational.  
 
Safety 
10 
 
There were a total of 7 adverse events during this study (Table 7). Capsule retention occurred in 3 
patients (2.9%) and all three cases occurred in patients who ingested the PC first. One of these 
cases involved retention of both capsules in the esophagus. Upper endoscopy was performed 
and both capsules were successfully removed using a net. No obvious stricture or obstructing 
lesion was seen in the esophagus. A manometric study was not performed in this patient. The 
remaining two cases of capsule retention were secondary to enteric strictures and required 
surgical removal of both capsules. There was one case of cardiac arrest one day after capsule 
ingestion, in which the patient was found to be in atrial fibrillation. The patient had an underlying 
history of cardiac disease, and after transfer and appropriate treatment in the ICU, the patient 
incurred no lasting sequelae. There was one case of epigastric abdominal pain, however an 
abdominal x-ray demonstrated the MC to be in the rectum, while the PC appeared to have 
already been expelled.  There was a mild case of contact dermatitis that resolved with removal of 
the adhesive sensors after completion of the capsule endoscope study. There was one instance 
of a skin blister at the waist line away from any adhesives used for the study, which could not be 
definitively attributed to either MC or PC. There were no deaths reported in the course of this 
study. There was no evidence that either capsule hindered in the diagnostic accuracy of the other 
capsule due to capsule collision or interference in the operational quality of the other capsule.  
 
DISCUSSION: 
This study is the first US study to evaluate the MiroCam®, a novel capsule endoscope which 
utilizes electric-field propagation for signal transmission, and to directly compare it to the existing 
PC capsule endoscopic technology. This study demonstrates that MC is safe, has a significantly 
longer operational life than PC, and is concordant with PC for the diagnosis of OGIB. 
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The study was designed for an estimated concordance rate of 85% between the two capsules. 
However, the actual rate of agreement found in this trial was 78.7% (k value of 0.55), a result that 
is in line with the concordance rate found in a study that compared the Olympus Endocapsule to 
PillCam SB1. In that study, the overall agreement rate was 74.5% (k value of 0.48) 2. Similar to the 
previous study, we demonstrated both intra-capsule and inter-capsule disagreement in a number 
of patients. These types of issues are likely to be unavoidable in studies of this nature.  
Furthermore, the interpretation of still images from a capsule endoscope is likely to involve a 
significant subjective opinion by the readers in the study.  
 
In evaluating the transit times of the two capsules through various anatomic landmarks, there 
were no significant differences in transit times to the small bowel (first duodenal image) or to 
capsule expulsion per rectum (Table 6). However, there was a significant difference in transit 
time to first cecal image (6.3 hours for MC and 5.2 hours for PC, p < 
0.0001).  An explanation for this 1.1 hour longer transit time in the small bowel may again be due 
to the smaller dimensions of the MC (Table 2). The smaller MC may be sufficiently large to 
ultimately be propelled through the small bowel; however, there may be some “slippage” with 
each peristalsis that results in the MC to linger in the small bowel for greater time periods. 
Nevertheless, despite this longer transit time, the MC did not result in a statistically significant 
fewer number of MC capsules with complete small bowel examinations (p = 0.10). Rather, there 
was a 9% higher rate of MC’s complete examination of the small bowel: 93.3% of MC capsules 
reached the cecum in contrast to 84.3% of PC capsules. The diagnostic yield of the MC at 40.4% 
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was also similar to PC, which detected an abnormality in 34.8% of cases (difference not 
statistically significant). 
 
If the yield for abnormal cases is assessed for at least one capsule being positive for a lesion, 
there were 43 abnormal cases or 48.3% of the study patients. The detection of abnormalities was 
somewhat lower in this study compared to previous rates seen in the literature which range from 
50-65% 2,4-6. The reasons for this lower rate of yield for abnormal cases is unclear, although it is 
likely influenced by the case mix and referral patterns for capsule studies at these centers.  
 
One possible benefit that the MC offers is the larger number of images generated coupled with a 
significant increase of operational time. Although the exact number of images generated by each 
capsule was not collected, some simple calculations can be made to extrapolate this difference. 
Since the total operation time of the MC was 3.3 hours longer than the PC and with the MC 
generating 3 images per second versus 2 images per second, this roughly correlates with greater 
than 63,000 more images generated by MC. Additionally, the small intestinal transit time of the 
MC was longer than PC by 1.1 hours. This alone would roughly correlate with more than 30,000 
small bowel images generated by MC. The MC also has a higher resolution image in comparison 
to PC (Table 2). Overall, there were 12 missed lesions by PC that MC identified, whereas there 
were 7 cases that MC missed that were identified by PC. These aforementioned factors may, in 
part, explain this 42% reduction in “missed” lesions with the MC. This argument, however, can be 
countered by whether there is a substantial and statistically significantly increased reading time 
and whether the increased efforts of reading more images is worth this incremental increase in 
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detected lesions. In this study, the time to read each capsule study was not recorded and further 
studies to examine this difference need to be performed. 
 
Prior studies have demonstrated upwards of 16-22% rates of incomplete small bowel 
examinations 7-10. The PC was in line with these prior studies as it demonstrated a 15.7% rate of 
failure to achieve complete small bowel examination. On the contrary, the incompletion rate for 
MC was only 7% (6/89). This difference was felt to be a result of the lower battery consumption, 
based on the electric-field propagation technology used by MC to transmit data, allowing for a 
significantly longer operational time (Figure 2) and a trend toward a higher rate of complete 
small bowel examinations.  
 
The safety profile is in line with what is expected of capsule endoscopy done with PC in the 
clinical setting, with the key adverse event being capsule retention.  Interestingly, all three 
episodes of capsule retention (2.9% of all test subjects) occurred in the cohort that ingested the 
PC first. In each case, both capsules were retained and thus, it is uncertain if the MC had been the 
lead capsule in these cases whether the MC would have been retained as well. Two prior 
published studies involving MC demonstrated no cases of MC capsule retention 3,11. Although 
some of this may be as a direct result of fortuitous patient selection or small sample sizes in 
these prior studies, one putative explanation may be the smaller external dimensions of the MC 
capsule compared to the PC (Table 2).  
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The main limitation to this study was the inability to blind readers to the particular capsule they 
were reading. This was an expected limitation and one that could not be overcome, due to 
differences in the computer interface, shape of the capsule image generated, and image 
resolutions. Nevertheless, the readers were blinded to the patient’s identity, and the reading of 
the second capsule for any given patient was separated in time in a randomized fashion by study 
design. Importantly, none of the readers had any financial or professional affiliation with MC or 
its manufacturer, reducing any positive bias towards MC.  A second limitation to this study is that 
it was not sufficiently powered to determine whether there was a difference in complete small 
bowel examination.  
 
In conclusion, the two capsules demonstrated comparable diagnostic yield and utility. The MC 
with its electric field propagation technology was safe in clinical use. The lower energy system 
technology allowed for a statistically significantly longer operational time, and demonstrated 
comparable rates of detecting small bowel lesions and complete small bowel examinations.  
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Table 1. Patient demographics and characteristics. 
         Parameter MiroCam First PillCam First Total p-value   
 
Age (years) 
   
0.6536 
 
 
           Number of subjects (n) 52 53 105 
  
 
           Mean (STD) 60.3 (15.89) 62.8 (12.85) 61.5 (14.42) 
  
 
           Median 63.0 63.0 63.0 
  
 
           Minimum - Maximum 22.0 - 87.0 28.0 - 87.0 22.0 - 87.0 
  
       
 
Gender (n%) 
   
1.0000 
 
 
           Male            28 (53.8) 29 (54.7) 57 (54.3) 
  
 
           Female 24 (46.2) 24 (45.3) 48 (45.7) 
  
       
 
Ethinicity (n%) 
   
0.5247 
 
 
           White  37 (71.2) 38 (71.7) 75 (71.4) 
  
 
           Native Hawaiian / Other Pacific 
Islander 0 (0.0) 0 (0.0) 0 (0.0) 
  
 
           Black 7 (13.5) 3 (5.7) 10 (9.5) 
  
 
           Hispanic 6 (11.5) 7 (13.2) 13 (12.4) 
  
 
           Asian 2 (3.8) 2 (3.8) 4 (3.8) 
  
 
           American Indian / Alaskan Native 
American 0 (0.0) 2 (3.8) 2 (1.9) 
  
 
           Other 0 (0.0) 1 (1.9) 1 (1.0) 
  
       
 
Height (inches) 
   
0.4815 
 
 
           n 52 53 105 
  
 
           Mean (STD) 66.1 (6.33) 65.9 (4.26) 66.0 (5.37) 
  
 
           Median 66.5 66.0 66.0 
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           Minimum - Maximum 34.0 - 74.5 56.0 - 77.0 34.0 - 77.0 
  
       
 
Weight  (lbs) 
   
0.4193 
 
 
           n 52 53 105 
  
 
           Mean (STD) 173.5 (46.34) 187.8 (54.73) 180.7 (51.01) 
  
 
           Median 170.0 170.0 170.0 
  
 
           Minimum - Maximum 52.0 - 313.9 110.0 - 332.0 52.0 - 332.0 
  
       
 
Pregnancy (n%) 
     
 
           Negative 5 (9.6) 3 (5.7) 8 (7.6) 
  
 
           Positive 0 (0.0) 0 (0.0) 0 (0.0) 
  
 
           Pregnancy test not performed 
(reason) 47 (90.4) 50 (94.3) 97 (92.4) 
  
 
                      Male 28 (53.8) 29 (54.7) 57 (54.3) 
  
 
                      Post-menopausal 17 (32.7) 18 (34.0) 35 (33.3) 
  
 
                      Surgically sterile 2 (3.8) 3 (5.7) 5 (4.8) 
  
 
                      Other 0 (0.0) 0 (0.0) 0 (0.0) 
  
       
 
Occult bleeding (n%) 17 (32.7) 18 (34.0) 35 (33.3) 1.0000 
 
       
 
Overt bleeding (n%) 20 (38.5) 23 (43.4) 43 (41.0) 0.6926 
 
       
 
Iron deficiency anemia (n%) 46 (88.5) 49 (92.5) 95 (90.5) 0.5260 
 
       
 
Blood transfusion within last 3 months (n%) 29 (55.8) 28 (52.8) 57 (54.3) 0.8454 
 
       
 
Hemoglobin prior to last transfusion  (g/dL) 
   
0.1777 
 
 
           n 28 27 55 
  
 
           Mean (STD) 7.5 (1.80) 8.2 (1.49) 7.9 (1.68) 
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           Median 7.2 7.8 7.8 
  
 
           Minimum - Maximum 3.8 - 11.0 5.4 - 11.3 3.8 - 11.3 
  
       Table 2. Characteristics of MiroCam and PillCam. 
 
 
PC MC 
Length (mm) 26.0 24.0 
Diameter (mm) 11.0 10.8 
Weight (g) 3.45 3.30 
Frame rate (frames/s) 2 3 
Image resolution (pixels) 256x256 320x320 
 
Table 3. Number of normal and abnormal results by capsule type. 
      
 
    PillCam   
 
 
MiroCam Normal Abnormal Total 
 
 
Normal 46 7 53 
 
 
Abnormal 12 24 36 
 
 
Total 58 31 89 
 
       
Table 4: Overall, positive and negative agreements. 
       Total  
 
Parameter N=89 
 
 
Overall agreement (n%) 70/89 (78.65%) 
 
 
95% lower confidence limit ** 68.69% 
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95% upper confidence limit ** 86.63% 
 
    
 
Positive agreement (n%)* 24/31 (77.42%) 
 
 
95% lower confidence limit ** 58.90% 
 
 
95% upper confidence limit ** 90.41% 
 
    
 
Negative agreement (n%)* 46/58 (79.31%) 
 
 
95% lower confidence limit ** 66.65% 
 
 
95% upper confidence limit ** 88.83% 
 
     
* Agreement was assessed by comparing the two independent readers' responses for each capsule to the question: 'Were you able  
to identify the primary cause of small bowel bleeding? (Yes/No) ' . 
**CI computed using Exact Binomial Test. 
 
Table 5. Types of lesions identified by capsule type. 
          
 
        PillCam       
 
 
MiroCam Normal 
Ulcerative 
lesions Tumor/Polyp 
Vascular 
lesions 
Blood - lesion 
unidentified Other Total 
 
 
Normal 46 0 1 3 3 0 53 
 
 
Ulcerative lesions 2 4 0 0 0 0 6 
 
 
Tumor/Polyp 1 0 1 1 0 0 3 
 
 
Vascular lesions 6 0 0 9 0 0 15 
 
 
Blood - lesion unidentified 3 0 0 1 6 0 10 
 
 
Other 0 0 0 0 2 0 2 
 
 
Total 58 4 2 14 11 0 89 
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Table 6. Transit times. 
                 
        MiroCam   PillCam p-value**** ICR***** 
        (N=89)   (N=89)   25
th
/75
th
 percentiles 
Esophageal transit time (minutes)          
  N     88*   87* NS 0.20 / 0.40 
 
Mean (SD)   1.4 (6.6)   1.1 (2.0) 0.0183  
 Median     0.3   0.6    
  Minimum-Maximum 0.0-61.2   0.1-18.0    
                 
Gastric transit time (minutes)            
  N     89   88** NS 164.5 / 95.6 
  Mean (SD)   58.9 (66.4)   44.0 (56.0) NS  
  Median     30.2   21.5    
 
Minimum-Maximum 1.1-366.3   1.3-304.6    
                
Small bowel transit time (hours)         3.0 / 2.1 
  N     83   75 NS  
 
Mean (SD)   6.6 (2.2)   5.2 (1.4) <0.0001  
 Median     6.3   5.1    
  Minimum-Maximum 2.3-11.8   2.4-7.9    
                 
Total transit time (hours) ***           70.7 / 70.5 
  N     74   74 NS  
  Mean (SD)   115.3   
108.5 
(147.1) NS 
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  Median     53.5   45.8    
  Minimum-Maximum 5.2-742.6   3.1-652.7    
                 
Total operation time             
  N     89   89 NS 10.6 / 0.10 
  Mean (SD)   11.1 (1.5)   7.8 (0.8) <0.0001  
 
Median     11.4   7.9    
 Minimum-Maximum 5.1-12.0   3.7-10.0    
                 
 
* A MiroCam capsule was retained in the esophagus for 139 minutes and a PillCam capsule was retained in 
the esophagus for 261 minutes 
** In one subject, the first image recorded by Pillcam was a duodenal image. As a result, no esophageal or 
gastric transit time could be recorded in which an esophageal time could not be recorded  
*** Time to capsule expulsion from the body 
**** The p-value refers to the log-rank test comparing the two distributions with respect to the time to 
event listed. 
***** IQR: interquartile range with the 25
th
 and 75
th
 percentiles of the distribution of times to the events 
 
 
Table 7. Adverse events. 
           
      Attribution 
Adverse Event*   (n %)   
Total 
MiroCam (MC), 
PillCam (PC), 
    
(n=105) 
 Unknown (U), Both 
(B) 
Subjects with any events   7 (6.7%)   
  
 
   
  
 
21 
 
        
Retention of Capsule   3 (2.9%) B 
Cardiac arrest   1 (1.0%) U 
Skin blister at waist line   1 (1.0%) U 
Contact dermatitis   1 (1.0%) M 
Nausea   0 (0.0%)   
Vomiting   0 (0.0%)   
Abdominal Pain   1 (1.0%) U 
Dizziness   0 (0.0%)   
Syncope   0 (0.0%)   
Intestinal Perforation   0 (0.0%)   
Aspiration into Airway   0 (0.0%)   
        
  
 
Figure 1. Randomization of patients. 
 
1One subject was allowed to enroll twice; therefore 2 subject identification numbers were assigned.  Subject data only 
reported once. 2One subject terminated the study early but had evaluable reader data (subject did not return for 
abdominal x-ray to confirm capsule passage and was lost-to-follow-up)3 One subject terminated the study early and did 
not have evaluable reader data (subject could not swallow first capsule and withdrew) 4One subject’s imaging files 
would not upload to the receiver due to technical issues and two subjects had one or more capsules that did not reach the 
small bowel while operational. 
 
  
 
Figure 2. Product Limit Survival Estimates 
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